Distinguishing aneugenic (chromosomes loss) from clastogenic effects (DNA damages) is essential to assess genotoxic properties of compounds. In order to help you taking the right decisions for your compounds, we developed a multiplex assay in Read more…
Come and discover our programs on iPS and 3D culture
Last friday (10/11), we presented our neurotoxicity and genotoxicity assays at the French Agency for Food and Safety (ANSES)
We saw and participated to very interested sessions about genotoxic and epigenetic effects of environmental compounds
Genotoxicity potential assessment of pharmaceuticals is mandatory for registration. In addition to the standard in vitro/ in vivo test battery, other assays can be of interest because of their high throughput in the drug discovery stage but also for mechanistic understanding.
If you are in Cosm'ing meeting, don't hesitate to go and discuss with Julian BURSZTYKA, our COO
During ELRIGfr event in Rennes, We had the opportunity to present our work on genotoxicity assay (comet assay on TK6 & gH2AX on keratinocytes and HepG2) in collaboration with the team of in vitro of Read more…
Quantifying DNA damage is mandatory to assess potential adverse effects of candidate drugs or molecules or extracts developed in the dermo-cosmetic industry, but also to assess the efficacy of therapeutic approaches with the aim of producing tumor cell genotoxicity in cancer treatment.
I was present at the last congress ELRIGfr in Brussels. It was a strong exchange place with interesting presentations around robotics. It is always really interesting to see examples of innovative automation which give really robust results.
Nathalie and Julian were present during ELRIGfr event last week. They presented their company, their work and their collaborations. They have also presented two posters, one on co-culture model of Parkinson and first results in 3D dimension, and the other one, on genotoxicity and steatosis assay on HepG2 cells.
